Find a Research Lab

Enter a research interest, principal investigator or keyword

Displaying 1 to 8 of 8 results for antigens

Show: 10 · 20 · 50

  1. 1
  • Cervical Cancer Research Lab

    Johns Hopkins is a member of the Specialized Program of Research Excellence (SPORE) in Cervical Cancer. With a $11.5 million grant from the National Cancer Institute, we are conducting lab, translational and clinical studies to prevent and treat cervical cancers. Previous studies have identified connections between immune system genes and HPV16. Current projects include the development of next-generation HPV vaccines to control HPV-associated precursor lesions and invasive cancer. Our dedicated researchers are working to extend the techniques used in HPV vaccine development to the creation of vaccines targeting other cancers with defined tumor antigens.

    Research Areas: HPV vaccines, cervical cancer, HPV

    Lab Website

    Principal Investigator

    Tzyy-Choou Wu, M.D., M.P.H., Ph.D.

    Department

    Pathology

  • Cervical Dysplasia Research Lab

    We are interested in how immune responses occur in the cervix. The focus of our translational research is on developing immune therapies for disease caused by human papillomavirus (HPV). HPV infection causes more cancers than any other virus in the world. Cervical cancer is the most common cancer caused by HPV, and although we have known how to screen for it for over half a century, it remains the second most common cause of cancer death in women. Although the preventive vaccines are a public health milestone, they prevent HPV infections, but are not designed to make immune responses to treat HPV. We are testing different strategies to make immune responses that could treat HPV disease. Our dedicated researchers are working to extend the techniques used in HPV vaccine development to the creation of vaccines targeting other cancers with defined tumor antigens.

    Research Areas: cervical cancer, HPV, cancer vaccines

  • Drew Pardoll Lab

    The Pardoll Lab focuses on the regulation of antigen-specific T cell responses and studies approaches to modify these responses for immunotherapy. Pardoll has a particular interest in cancer immunology and his lab’s studies on basic immunologic mechanisms have led to the development and design of a number of cancer vaccines and discovery of key checkpoint ligands and receptors, such as PD-L2, LAG-3 and neuritin, many of which are being targeted clinically.

    Our primary pursuits are discovering and elucidating new molecules that regulate immune responses, investigating the biology of regulatory T cells, and better understanding the specific biochemical signatures that allow a patient’s T cells to selectively target cancer cells.

    Research Areas: tumor antigens, cancer, immunotherapy, regulatory T cells, T cells

    Principal Investigator

    Drew Pardoll, M.D., Ph.D.

    Department

    Medicine
    Oncology
    Pathology

  • Elizabeth M. Jaffee, M.D.

    Current projects include:

    The evaluation of mechanisms of immune tolerance to cancer in mouse models of breast and pancreatic cancer. We have characterized the HER-2/neu transgenic mouse model of spontaneous mammary tumors.
    This model demonstrates immune tolerance to the HER-2/neu gene product. This model is being used to better understand the mechanisms of tolerance to tumor. In addition, this model is being used to develop vaccine strategies that can overcome this tolerance and induce immunity potent enough to prevent and treat naturally developing tumors. More recently, we are using a genetic model of pancreatic cancer developed to understand the early inflammatory changes that promote cancer development.

    The identification of human tumor antigens recognized by T cells. We are using a novel functional genetic approach developed in our laboratory. Human tumor specific T cells from vaccinated patients are used to identify immune relevant antigens that are chosen... based on an initial genomic screen of overexpressed gene products. Several candidate targets have been identified and the prevelence of vaccine induced immunity has been assessed .
    This rapid screen to identify relevant antigenic targets will allow us to begin to dissect the mechanisms of tumor immunity induction and downregulation at the molecular level in cancer patients. More recently, we are using proteomics to identify proteins involved in pancreatic cancer development. We recently identified Annexin A2 as a molecule involved in metastases.

    The analysis of antitumor immune responses in patients enrolled on vaccine studies. The focus is on breast and pancreatic cancers. We are atttempting to identify in vitro correlates of in vivo antitumor immunity induced by vaccine strategies developed in the laboratory and currently under study in the clinics.
    view more

    Research Areas: immunology, cancer, anti-cancer drugs

    Lab Website

    Principal Investigator

    Elizabeth Jaffee, M.D.

    Department

    Oncology

  • Michael Edidin Lab

    The Michael Edidin Lab studies membrane dynamics and organization in cells from lymphocytes to epithelial cells using biochemistry, biophysics (especially fluorescence methods), cell biology, biochemistry and immunology. We are interested in transplantation immunology, particularly in the cell biology of class I MHC molecules, and are working to understand the relationship between plasma membrane biophysics and antigen presentation by MHC molecules. We are currently studying the clustering of T cell receptors for the antigen TCR.

    Research Areas: biochemistry, cell biology, membrane biophysics, MHC molecules, antigens, T cells

    Principal Investigator

    Michael Edidin, Ph.D.

    Department

    Medicine

  • Peter Agre Lab

    Work in the Peter Agre Lab focuses on the molecular makeup of human diseases, particularly malaria, hemolytic anemias and blood group antigens. In 2003, Dr. Agre earned the Nobel Prize in Chemistry for discovering aquaporin water channels. Building on that discovery, our recent research has included studies on the protective role of the brain water channel AQP4 in murine cerebral malaria, as well as defective urinary-concentrating ability as a result of a complete deficiency in aquaporin-1. We also collaborate on scientific training and research efforts with 20 Baltimore-area labs and in field studies in Zambia and Zimbabwe.

    Research Areas: infectious disease, anemia, malaria

    Principal Investigator

    Peter Agre, M.D.

    Department

    Biological Chemistry

  • Schneck Lab

    Effective immune responses are critical for control of a variety of infectious disease including bacterial, viral and protozoan infections as well as in protection from development of tumors. Central to the development of an effective immune response is the T lymphocyte which, as part of the adaptive immune system, is central in achieving sterilization and long lasting immunity. While the normal immune responses is tightly regulated there are also notable defects leading to pathologic diseases. Inactivity of tumor antigen-specific T cells, either by suppression or passive ignorance allows tumors to grow and eventually actively suppress the immune response. Conversely, hyperactivation of antigen-specific T cells to self antigens is the underlying basis for many autoimmune diseases including: multiple sclerosis; arthritis; and diabetes. Secondary to their central role in a wide variety of physiologic and pathophysiologic responses my lab takes a broad-based approach to studying T cell re...sponses. view more

    Research Areas: t-cell responses, pathologic diseases, autoimmune diseases, pathology, immune system

    Lab Website

    Principal Investigator

    Jonathan Schneck, M.D., Ph.D.

    Department

    Pathology

  • Zsuzsanna McMahan Lab

    The Zsuzsanna McMahan Lab conducts translational research that seeks to identify the novel antigens in scleroderma and to define the target tissue in this disease. We are conducting two active clinical research trials, including one that studies skin biopsy specimens as biomarkers of scleroderma and the response to mycophenolate mofetil (MMF or Cellcept). The other study is a gastrointestinal involvement registry that follows patients who are experiencing GERD, small bowel bacterial overgrowth, constipation, fecal incontinence and gastroparesis to see if there is improvement in symptoms after a change in treatment is implemented.

    Research Areas: gastrointestinal system, rheumatology, biomarkers, scleroderma, antigens, mycophenolate mofetil

    Lab Website

    Principal Investigator

    Zsuzsanna McMahan, M.D., M.H.S.

    Department

    Medicine

  1. 1